Results 181 to 190 of about 70,470 (286)

Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell‐Based Therapies

open access: yesThe FASEB Journal, Volume 40, Issue 6, 31 March 2026.
Graphical presentation of stem cell‐based therapies for arterial dysfunction, endothelial repair and regeneration strategies. SMC, smooth muscle cell. ABSTRACT Arterial regeneration represents a critical frontier in cardiovascular medicine, as progressive endothelial dysfunction, maladaptive vascular smooth muscle cell (SMC) plasticity, and chronic ...
Yun‐Yu Ma, Shu‐Yao Zhu, Yi Song
wiley   +1 more source

Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide‐Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients

open access: yesPediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Background Cyclophosphamide (CY) is associated with potentially fatal cardiotoxicity, yet no electrocardiographic indices have been established for early detection of CY‐induced cardiomyopathy. This study aimed to determine whether corrected QT interval (QTc) prolongation can predict early onset of CY‐related cardiac dysfunction in pediatric ...
Junpei Kawamura   +5 more
wiley   +1 more source

NT-proBNP and Myocardial Fibrosis

open access: yesJournal of the American College of Cardiology, 2017
openaire   +1 more source

Therapeutic Dilemmas in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Diffuse Alveolar Hemorrhage and Venous Thromboembolism

open access: yesACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Diffuse alveolar hemorrhage (DAH) is a life‐threatening presentation of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Patients with AAV are at an increased risk of venous thromboembolic events (VTEs). These manifestations can co‐occur; however, the prognosis and management of these patients are poorly understood. Methods In
Elif D. Ediboglu   +5 more
wiley   +1 more source

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy

open access: yesAmerican Journal of Hematology, Volume 101, Issue 3, Page 512-520, March 2026.
Early cardiac biomarker monitoring in AML induction therapy showed significantly higher hsTnT levels after daunorubicin 90 mg/m2 compared with 60 mg/m2, indicating a dose‐dependent early myocardial effect. ABSTRACT Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the ...
Stefan Markus Dendorfer   +44 more
wiley   +1 more source

Home - About - Disclaimer - Privacy